These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 6496235)

  • 21. A profile of the substance abuse treatment industry: organization, costs, and treatment completion.
    Woodward AM; Raskin IE; Blacklow B
    Subst Use Misuse; 2008; 43(5):647-79. PubMed ID: 18393082
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Prospective study of favorable factors in follow-up of drug addicted patients--apropos of 257 patients of the Cassini Center in Paris].
    Goeb JL; Coste J; Bigot T; Ferrand I
    Encephale; 2000; 26(6):11-20. PubMed ID: 11217533
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cost-effectiveness analysis of integrated care for people with HIV, chronic mental illness and substance abuse disorders.
    Weaver MR; Conover CJ; Proescholdbell RJ; Arno PS; Ang A; Uldall KK; Ettner SL
    J Ment Health Policy Econ; 2009 Mar; 12(1):33-46. PubMed ID: 19346565
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The impact of contracting and prompting substance abuse treatment entry: a pilot trial.
    Lash SJ; Gilmore JD; Burden JL; Weaver KR; Blosser SL; Finney ML
    Addict Behav; 2005 Mar; 30(3):415-22. PubMed ID: 15718059
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Substance abuse treatment for Ontario residents in the United States.
    Rush B; Tyas S; Martin G
    Addiction; 1996 May; 91(5):671-85. PubMed ID: 8935252
    [TBL] [Abstract][Full Text] [Related]  

  • 26. New directions in alcohol and drug treatment under managed care.
    Weisner C; McCarty D; Schmidt L
    Am J Manag Care; 1999 Jun; 5 Spec No():SP57-69. PubMed ID: 10538861
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Utilization and cost impact of integrating substance abuse treatment and primary care.
    Parthasarathy S; Mertens J; Moore C; Weisner C
    Med Care; 2003 Mar; 41(3):357-67. PubMed ID: 12618639
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of centralized intake on outcomes of substance abuse treatment.
    Rohrer JE; Vaughan MS; Cadoret RJ; Carswell C; Patterson A; Zwick J
    Psychiatr Serv; 1996 Nov; 47(11):1233-8. PubMed ID: 8916242
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cost-effectiveness of public sector substance abuse treatment: comparison of a managed care approach to a traditional public sector system.
    Beattie MC; Hu TW; Li R; Bond JC
    J Behav Health Serv Res; 2005; 32(4):409-29. PubMed ID: 16215450
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Reduced substance-abuse-related health care costs among voluntary participants in Alcoholics Anonymous.
    Humphreys K; Moos RH
    Psychiatr Serv; 1996 Jul; 47(7):709-13. PubMed ID: 8807683
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cost-effectiveness analysis of addiction treatment: paradoxes of multiple outcomes.
    Sindelar JL; Jofre-Bonet M; French MT; McLellan AT
    Drug Alcohol Depend; 2004 Jan; 73(1):41-50. PubMed ID: 14687958
    [TBL] [Abstract][Full Text] [Related]  

  • 32. "Intensive" outpatient substance abuse treatment: comparisons with "traditional" outpatient treatment.
    McLellan AT; Hagan TA; Meyers K; Randall M; Durell J
    J Addict Dis; 1997; 16(2):57-84. PubMed ID: 9083825
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Satisfaction of impaired health care professionals with mandatory treatment and monitoring.
    Fletcher CE; Ronis DL
    J Addict Dis; 2005; 24(3):61-75. PubMed ID: 16186083
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evaluation of full vs. partial continuum of care in the treatment of publicly funded substance abusers in Washington State.
    McKay JR; Donovan DM; McLellan T; Krupski A; Hansten M; Stark KD; Geary K; Cecere J
    Am J Drug Alcohol Abuse; 2002; 28(2):307-38. PubMed ID: 12014818
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Out of touch or on the money: Do the clinical objectives of addiction treatment coincide with economic evaluation results?
    Dismuke CE; French MT; Salomé HJ; Foss MA; Scott CK; Dennis ML
    J Subst Abuse Treat; 2004 Oct; 27(3):253-63. PubMed ID: 15501378
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The impact of substance user treatment participation on legal employment and income among probationers and parolees.
    Sung HE; Chu D
    Subst Use Misuse; 2011; 46(12):1523-35. PubMed ID: 21428743
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A discrete choice model of drug abuse treatment location.
    Goodman AC; Nishiura E; Hankin JR
    Health Serv Res; 1998 Apr; 33(1):125-45. PubMed ID: 9566181
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A comparative, process-effectiveness evaluation of VA substance abuse treatment.
    Finney JW; Ouimette PC; Humphreys K; Moos RH
    Recent Dev Alcohol; 2001; 15():373-91. PubMed ID: 11449754
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Combined Alcoholics Anonymous and professional care for addicted physicians.
    Galanter M; Talbott D; Gallegos K; Rubenstone E
    Am J Psychiatry; 1990 Jan; 147(1):64-8. PubMed ID: 2293790
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Alcoholism treatment and total health care utilization and costs. A four-year longitudinal analysis of federal employees.
    Holder HD; Blose JO
    JAMA; 1986 Sep; 256(11):1456-60. PubMed ID: 3747063
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.